Heart attack, stroke or cancer. Take your pick. That was the choice I was being offered, or so it seemed. I'm one of hundreds of patients who were participating in clinical trials to investigate whether COX-2 inhibitors such as Celebrex and Vioxx, commonly used as anti-inflammatory drugs, are also effective in fighting or preventing cancer. But the trials were halted last year after reports that the risk of heart attack or stroke doubled among a group of Vioxx users. Vioxx was summarily yanked from the market and the tort lawyers immediately canceled lunch. Celebrex was also implicated because it's in the...
To continue reading:
or
Log-In
